false
Catalog
What Do the Trials Say for Catheter Ablation?
What's New in Managing the LAA — An Update on the ...
What's New in Managing the LAA — An Update on the AMAZE Study (Presenter: David J. Wilber, MD, FHRS, CCDS)
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. David Wilber provides an update on the AMAZE trial, which focuses on the left atrial appendage and its role in atrial fibrillation (AF). The trial aims to determine the benefit of left atrial appendage isolation using the Lariat device in addition to pulmonary vein isolation for patients with persistent and long-standing persistent AF. The trial is currently ongoing, with 493 patients enrolled and an interim analysis planned for the 500-patient mark. The primary endpoints include freedom from AF and no requirement for new antiarrhythmic drugs. The trial's design also allows for assessment of the safety and effectiveness of left atrial appendage isolation.
Meta Tag
Lecture ID
6481
Location
Room 303
Presenter
David J. Wilber, MD, FHRS, CCDS
Role
Invited Speaker
Session Date and Time
May 10, 2019 10:30 AM - 12:00 PM
Session Number
S-058
Keywords
Dr. David Wilber
AMAZE trial
left atrial appendage
atrial fibrillation
Lariat device
Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
E: questions@heartrhythm365.org
© Heart Rhythm Society
Privacy Policy
|
Cookie Declaration
|
Linking Policy
|
Patient Education Disclaimer
|
State Nonprofit Disclosures
|
FAQ
×
Please select your language
1
English